William Blair analyst Andy Hsieh has reiterated their bullish stance on EXEL stock, giving a Buy rating on November 3.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andy Hsieh has given his Buy rating due to a combination of factors including the robust growth prospects of Exelixis’s Cabometyx franchise and the promising potential of Zanza. Cabometyx is expected to generate substantial cash flow through 2030, supported by its strong performance in the neuroendocrine tumors market, where it has captured a significant share of new patient prescriptions. Additionally, the company’s strategic focus on pivotal studies, such as those for post-adjuvant colorectal cancer and high-grade meningioma, positions it well for future growth.
Furthermore, Exelixis’s financial performance in the third quarter, with product sales reaching $543 million, underscores its solid market position. Although Cabometyx’s revenue was slightly below expectations, the company’s ability to manage gross-to-net adjustments effectively and maintain stable financial metrics reflects its operational strength. These factors collectively contribute to Andy Hsieh’s confidence in Exelixis’s long-term potential, justifying the Buy rating.
Hsieh covers the Healthcare sector, focusing on stocks such as Exelixis, Skye Bioscience, and Viking Therapeutics. According to TipRanks, Hsieh has an average return of 8.2% and a 45.81% success rate on recommended stocks.